Description
+ Include: 78 videos + 56 pdfs, size: 7.39 GB
+ Target Audience: oncologist
+ Sample video: contact me for sample video
+ Information:
- Start date 06 Mar 2023
- End date 08 Mar 2023
- Location Paris, France
ESMO Targeted Anticancer Therapies Congress 2023 took place on 6-8 March 2023 in Paris, France
ESMO TAT, known as “The Home of Phase I in Oncology”, is the leading congress focusing on promising new anticancer targets and agents, with a particular emphasis on those in early phase clinical development.
This congress was dedicated to improving the conduct of early anti-cancer clinical trials, bringing together those who are developing the most promising new cancer drugs and unveiling exciting new data.
With a record-breaking number of abstracts submitted, this edition offered a unique opportunity for stakeholders from academia and industry to discuss with clinicians, researchers, and regulators the global dissemination of knowledge and clinical research expertise in the field of innovative cancer therapeutics, to the benefit of cancer patients worldwide.
The ESMO Targeted Anticancer Therapies Congress 2023, is the premier international meeting focusing on promising new anticancer targets and agents, with a particular focus on those in early phase clinical development.
+ Topics:
Brain penetrance of drugs Chemical aspects of developing brain penetrant agents.mp4
Brain penetrance of drugs Chemical aspects of developing brain penetrant agents.pdf
Brain penetrance of drugs Immunotherapy for brain cancer Reimagining the pharmacological audit trail for drug delivery for brain tumours.mp4
Brain penetrance of drugs Immunotherapy for brain cancer Reimagining the pharmacological audit trail for drug delivery for brain tumours.pdf
Brain penetrance of drugs Q&A.mp4
Cell therapy Biomarkers for toxicities in cell therapy.mp4
Cell therapy Biomarkers for toxicities in cell therapy.pdf
Cell therapy Mechanisms of resistance in CAR-T.mp4
Cell therapy Mechanisms of resistance in CAR-T.pdf
Cell therapy Neoantigen specific TIL for solid tumours.mp4
Cell therapy Neoantigen specific TIL for solid tumours.pdf
Cell therapy Q&A.mp4
final_programme_tat2023.pdf
Keynote address Introduction to the Keynote lecture.mp4
Keynote address Novel insights in mutational signatures uncovered through whole genome sequencing of cancer and experimental models.mp4
Keynote address Novel insights in mutational signatures uncovered through whole genome sequencing of cancer and experimental models.pdf
Mini Oral session 28MO – Adapting the Time-to-Event Continual Reassessment Method (TiTE-CRM) to include consolidation.mp4
Mini Oral session 28MO – Adapting the Time-to-Event Continual Reassessment Method (TiTE-CRM) to include consolidation.pdf
Mini Oral session 70MO – Genomic profiling to expand precision cancer medicine in the real world The ROME trial.mp4
Mini Oral session 70MO – Genomic profiling to expand precision cancer medicine in the real world The ROME trial.pdf
Mini Oral session 79MO – Developing international consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding clinical trials.mp4
Mini Oral session 79MO – Developing international consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding clinical trials.pdf
Mini Oral session 80MO – Optimising participant flow diagrams for phase I clinical trials.mp4
Mini Oral session 80MO – Optimising participant flow diagrams for phase I clinical trials.pdf
Mini Oral session Invited Discussant.mp4
Mini Oral session Invited Discussant.pdf
Mini Oral session Oncology phase I trial design and conduct Time for a change – MDICT Guidelines 2022.mp4
Mini Oral session Oncology phase I trial design and conduct Time for a change – MDICT Guidelines 2022.pdf
Mini Oral session Panel discussion.mp4
Next-generation macro-molecules Biomarkers to predict response to ADCs.mp4
Next-generation macro-molecules Biomarkers to predict response to ADCs.pdf
Next-generation macro-molecules Human costimulatory bispecific antibodies in cancer immunotherapy.mp4
Next-generation macro-molecules Human costimulatory bispecific antibodies in cancer immunotherapy.pdf
Next-generation macro-molecules Q&A.mp4
Next-generation macro-molecules Radioligand therapy across disease Challenges and opportunities.mp4
Next-generation macro-molecules Radioligand therapy across disease Challenges and opportunities.pdf
Novel kinase inhibitors BRAF inhibitors Targeting class II III alterations.mp4
Novel kinase inhibitors BRAF inhibitors Targeting class II III alterations.pdf
Novel kinase inhibitors EGFR and or HER20 exon 20 inhibitors.mp4
Novel kinase inhibitors EGFR and or HER20 exon 20 inhibitors.pdf
Novel kinase inhibitors KRAS inhibitors beyond G12C.mp4
Novel kinase inhibitors KRAS inhibitors beyond G12C.pdf
Novel kinase inhibitors Q&A.mp4
Novel kinase inhibitors The latest on CDK 4 6 in breast cancer.mp4
Novel kinase inhibitors The latest on CDK 4 6 in breast cancer.pdf
Oral immunotherapy JAK inhibitors as IO therapy.mp4
Oral immunotherapy JAK inhibitors as IO therapy.pdf
Oral immunotherapy Oral PDL1 targeting.mp4
Oral immunotherapy Oral PDL1 targeting.pdf
Oral immunotherapy Q&A.mp4
Oral immunotherapy Small molecules to modulate TCR signalling.mp4
Oral immunotherapy Small molecules to modulate TCR signalling.pdf
Phase I trial methodology Advancement of statistical methodology and its practical implementation in phase I trials.mp4
Phase I trial methodology Advancement of statistical methodology and its practical implementation in phase I trials.pdf
Phase I trial methodology Pharmacodynamic endpoints in FIH trials.mp4
Phase I trial methodology Pharmacodynamic endpoints in FIH trials.pdf
Phase I trial methodology Q&A.mp4
Pre-clinical models and schedule testing Credentialing biomarkers for patient selection.mp4
Pre-clinical models and schedule testing Credentialing biomarkers for patient selection.pdf
Pre-clinical models and schedule testing Preclinical modelling to support contemporary drug development.mp4
Pre-clinical models and schedule testing Preclinical modelling to support contemporary drug development.pdf
Pre-clinical models and schedule testing Q&A.mp4
Predictive and pharmacodynamic biomarkers Biomarker role and potential of single-cell and spatially resolved multiparametric analysis.mp4
Predictive and pharmacodynamic biomarkers Biomarker role and potential of single-cell and spatially resolved multiparametric analysis.pdf
Predictive and pharmacodynamic biomarkers Q&A.mp4
Predictive and pharmacodynamic biomarkers Serum IL-8 as a predictive and pharmacodynamic circulating biomarker in cancer immunotherapy.mp4
Predictive and pharmacodynamic biomarkers Serum IL-8 as a predictive and pharmacodynamic circulating biomarker in cancer immunotherapy.pdf
Predictive and pharmacodynamic biomarkers Tumour microenvironment heterogeneity How to interpret as a biomarker.mp4
Predictive and pharmacodynamic biomarkers Tumour microenvironment heterogeneity How to interpret as a biomarker.pdf
Proffered Paper session 109O – Phase I study of MEDI9253, a recombinant Newcastle Disease Virus encoding interleukin-12.mp4
Proffered Paper session 109O – Phase I study of MEDI9253, a recombinant Newcastle Disease Virus encoding interleukin-12.pdf
Proffered Paper session 1O – Safety, pharmacokinetics, efficacy, and biomarker results of SRK-181 (a latent TGFá1 inhibitor) from a phase I trial (DRAGON trial).mp4
Proffered Paper session 1O – Safety, pharmacokinetics, efficacy, and biomarker results of SRK-181 (a latent TGFá1 inhibitor) from a phase I trial (DRAGON trial).pdf
Proffered Paper session 27O – First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors.mp4
Proffered Paper session 27O – First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors.pdf
Proffered Paper session Invited Discussant 1.mp4
Proffered Paper session Invited Discussant 1.pdf
Proffered Paper session Invited Discussant 2.mp4
Proffered Paper session Invited Discussant 2.pdf
Proffered Paper session Q&A.mp4
Prostate cancer How to manage prostate cancer in 2023.mp4
Prostate cancer How to manage prostate cancer in 2023.pdf
Prostate cancer Metabolic radiotherapy-lutetium-PSMA therapy.mp4
Prostate cancer Metabolic radiotherapy-lutetium-PSMA therapy.pdf
Prostate cancer Q&A.mp4
Prostate cancer Tumour genomic profiling What is relevant and how to avoid potential pitfalls.mp4
Prostate cancer Tumour genomic profiling What is relevant and how to avoid potential pitfalls.pdf
Prostate cancer Update on immune checkpoint inhibitors.mp4
Prostate cancer Update on immune checkpoint inhibitors.pdf
Seagen – ADCs’ journey into clinical use – Key considerations for improved outcomes An overview of current approaches utilizing ADCs.mp4
Seagen – ADCs’ journey into clinical use – Key considerations for improved outcomes Introduction.mp4
Seagen – ADCs’ journey into clinical use – Key considerations for improved outcomes Leveraging immune stimulatory ADCs to target immune checkpoints.mp4
Seagen – ADCs’ journey into clinical use – Key considerations for improved outcomes New ADC targets on the horizon.mp4
Seagen – ADCs’ journey into clinical use – Key considerations for improved outcomes Q&A and discussion.mp4
Viral related malignancies Cell-based immunotherapeutic approaches against HPV-associated targets (E7) in HPV-associated advanced cancers.mp4
Viral related malignancies Cell-based immunotherapeutic approaches against HPV-associated targets (E7) in HPV-associated advanced cancers.pdf
Viral related malignancies EBV-targeting and other immunotherapeutic approaches in the treatment of endemic nasopharyngeal carcinoma.mp4
Viral related malignancies EBV-targeting and other immunotherapeutic approaches in the treatment of endemic nasopharyngeal carcinoma.pdf
Viral related malignancies Immunotherapeutic advances in the treatment of advanced virally associated hepatocellular carcinoma.mp4
Viral related malignancies Immunotherapeutic advances in the treatment of advanced virally associated hepatocellular carcinoma.pdf
Viral related malignancies Q&A.mp4
Viral related malignancies Therapeutic vaccines and other non-cell based immunotherapeutic advances against HPV16 E7 and E6 in patients with solid cancers.mp4
Viral related malignancies Therapeutic vaccines and other non-cell based immunotherapeutic advances against HPV16 E7 and E6 in patients with solid cancers.pdf
Welcome to ESMO TAT 2023 and Honorary Award Epigenetic therapies Have they come of age.mp4
Welcome to ESMO TAT 2023 and Honorary Award Epigenetic therapies Have they come of age.pdf
Welcome to ESMO TAT 2023 and Honorary Award Introduction to the 2023 Honorary Award keynote lecture.mp4
Welcome to ESMO TAT 2023 and Honorary Award Introduction to the 2023 Honorary Award keynote lecture.pdf
Welcome to ESMO TAT 2023 and Honorary Award Presentation of 2020-2021-2022 Honorary Awards (Profs. Lillian Siu, Ruth Plummer, Lesley Seymour).mp4
Welcome to ESMO TAT 2023 and Honorary Award Presentation of 2020-2021-2022 Honorary Awards (Profs. Lillian Siu, Ruth Plummer, Lesley Seymour).pdf
Welcome to ESMO TAT 2023 and Honorary Award Welcome to ESMO TAT 2023.mp4
Welcome to ESMO TAT 2023 and Honorary Award Welcome to ESMO TAT 2023.pdf
Workshop in collaboration with ESMO YOC Data integrity and data sharing Artificial Intelligence How to use technology to obtain the truth.mp4
Workshop in collaboration with ESMO YOC Data integrity and data sharing Artificial Intelligence How to use technology to obtain the truth.pdf
Workshop in collaboration with ESMO YOC Data integrity and data sharing Q&A and discussion.mp4
Workshop in collaboration with ESMO YOC Data integrity and data sharing Research Integrity Does our system of peer-review and academic success contribute.mp4
Workshop in collaboration with ESMO YOC Data integrity and data sharing Research Integrity Does our system of peer-review and academic success contribute.pdf
Workshop in collaboration with ESMO YOC Drug repurposing trials International collaboration and data-sharing for rare targets.mp4
Workshop in collaboration with ESMO YOC Drug repurposing trials International collaboration and data-sharing for rare targets.pdf
Workshop in collaboration with ESMO YOC Drug repurposing trials Q&A and discussion.mp4
Workshop in collaboration with ESMO YOC Drug repurposing trials Why is this important Trials versus off-label use.mp4
Workshop in collaboration with ESMO YOC Drug repurposing trials Why is this important Trials versus off-label use.pdf
Workshop in collaboration with ESMO YOC How to bring new molecular entities to earlier stages of cancer Mermaid 1 & 2 design.mp4
Workshop in collaboration with ESMO YOC How to bring new molecular entities to earlier stages of cancer Mermaid 1 & 2 design.pdf
Workshop in collaboration with ESMO YOC How to bring new molecular entities to earlier stages of cancer Peri-operative endpoints.mp4
Workshop in collaboration with ESMO YOC How to bring new molecular entities to earlier stages of cancer Peri-operative endpoints.pdf
Workshop in collaboration with ESMO YOC How to bring new molecular entities to earlier stages of cancer Q&A and discussion.mp4
Workshop in collaboration with ESMO YOC Phase I design in the era of Project Optimus Importance, background.mp4
Workshop in collaboration with ESMO YOC Phase I design in the era of Project Optimus Importance, background.pdf
Workshop in collaboration with ESMO YOC Phase I design in the era of Project Optimus Practical recommendations.mp4
Workshop in collaboration with ESMO YOC Phase I design in the era of Project Optimus Practical recommendations.pdf
Workshop in collaboration with ESMO YOC Phase I design in the era of Project Optimus Q&A and discussion.mp4
Workshop in collaboration with ESMO YOC- Selecting patients with molecular imaging for anticancer treatment Q&A and discussion.mp4
Workshop in collaboration with ESMO YOC- Selecting patients with molecular imaging for anticancer treatment Selecting patients with molecular imaging for cancer.mp4
Workshop in collaboration with ESMO YOC- Selecting patients with molecular imaging for anticancer treatment Selecting patients with molecular imaging for cancer.pdf
Reviews
There are no reviews yet.